semaglutide heart failure trial Efficacy of by Sex in Obesity-Related With Preserved Ejection Fraction: STEP-HFpEF Trials FLOWing with the SemagluTIDE —

2 Strategies employed to develop GLP-1 receptor agonists with prolonged in vivo half-lives

A recent study shows people with obesity taking GLP-1 drugs are 20% less likely to suffer a cardiovascular event, and studies are under way for their use to treat the liver disease non-alcoholic steatohepatitis, as well as the neurodegenerative conditions Parkinsons and Alzheimers

Can non-surgical treatments like RF microneedling replace surgery for loose skin after weight loss

Ozempic is still only approved in the US for diabetes, though it is prescribed for weight loss

At the 3 month mark, the treatment group averaged between 6% and 8% reduction in body weight